LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

LAmbre™ LAA Closure System
Obtaining Approval for Pre-market Clinical Research in the US

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 15 May 2019, the Group's LAmbre™ Left Atrial Appendage (LAA) Closure System ("**LAmbre™ LAA Closure System**") obtained approval for an investigational device exemption ("**IDE**") application from the US Food and Drug Administration ("**FDA**"). IDE aims to provide preliminary confirmation that a device is safe for use in the human body by reviewing the pre-clinical data of the test device, thus allowing the medical device manufacturer to pass clinical trial observation and collect safety and effectiveness data of the test medical device by simpler means and providing support for pre-market approval application of medical device. Unless explicitly waived, all high-risk devices must apply for and obtain IDE approval from the FDA before clinical trials can be initiated in the US.

The Company obtaining successful approval of IDE marks the pioneering step for the LAmbre™ LAA Closure System to officially enter the US market. Once the product is approved for entry into the US market, we expect that it will bring strong performance growth to the Company, and will further promote and advance other outstanding innovative products of the Company to enter the US and other global mainstream markets.

LAmbre™ LAA Closure System has been self-developed by the Company over the past decade, and has advanced in product design and technology within the industry. The product has currently achieved satisfactory sales performance in the Chinese and

European markets, and is gradually entering the Southeast Asia and Latin America markets. The Company is confident that the product will obtain US market-entry approval from the FDA after completing pre-market clinical research in the US, and is looking forward to the launch of the product in the US market.

As the LAmbre™ LAA Closure System is still subject to further approval from the FDA, shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 20 May 2019

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.